1. FM-WEBSITE

Search Page

[current-page:query:search_api_aggregation_1]

Filter and Sort

Content type

661 - 670 of 2170
Paper

EFFECT OF LENALIDOMIDE EXPOSURE ON RESPONSE AND OUTCOMES IN PATIENTS WITH LOWER-RISK NON-DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS)

António Almeida 2017. LEUKEMIA RESEARCH
Paper

IMPACT OF GENE MUTATIONS ON RESPONSE TO LENALIDOMIDE AND OS IN LOWER-RISK NON-DEL(5Q) MDS PATIENTS INELIGIBLE/REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)

António Almeida 2017. LEUKEMIA RESEARCH
Paper

CLINICAL BENEFIT AMONG LENALIDOMIDE (LEN)-TREATED PATIENTS (PTS) WITH RBC TRANSFUSION-DEPENDENT (RBC-TD) LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT DEL(5Q)

António Almeida 2016. HAEMATOLOGICA
Paper

Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS)

António Almeida 2016. BLOOD
Paper

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

António Almeida 2016. BLOOD